Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study

Pituitary. 2018 Oct;21(5):454-462. doi: 10.1007/s11102-018-0898-y.

Abstract

Purpose: Lactotroph adenomas (LA) are the most frequently encountered pituitary tumors. Although more frequently observed in women, LAs in men were recently included in a more aggressive category regardless of histological grading, by the WHO. We aimed to perform a rigorous retrospective review of a single center's pre-operative evaluation, patient characteristics and outcomes of male LAs patients requiring pituitary surgery.

Methods: A retrospective review, over 11 years, of patients who underwent resection of a pituitary adenoma at a single center was conducted. Predictors of persistent disease in male LAs patients along with a comparison to predictors of silent corticotroph adenomas (SCAs) patients who also underwent surgery at the center was also conducted.

Results: Thirty-one male patients with LAs were identified. When compared to SCAs patients, LAs male patients were younger (41 vs. 50 years of age, p = 0.01). Men with LAs had more invasive tumors (75% vs. 44.7% p = 0.02). More LAs in men had residual tumor after surgery than patients with SCA (92.6% vs. 42.1%, p < 0.001). Male patients with LAs and patients with SCA had similar rates of requiring additional surgery (28.9% vs. 24.1%, p = NS) and radiation therapy (18.4% vs. 19.4%, p = NS).

Conclusions: High rates of DA resistance, invasive tumors and postoperative residual disease in male patients with LA who required surgery are shown. Surgery improved optic chiasm compression, PRL level and central hypogonadism but, not surprisingly, failed to normalize other pituitary hormones and/or eliminate need for DA therapy.

Keywords: Corticotroph adenomas; Dopamine agonist intolerance; Dopamine agonist resistance; Lactotroph adenomas; Males; Prolactinomas.

MeSH terms

  • ACTH-Secreting Pituitary Adenoma / drug therapy
  • ACTH-Secreting Pituitary Adenoma / pathology
  • ACTH-Secreting Pituitary Adenoma / surgery
  • Adult
  • Dopamine Agonists / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Pituitary Gland / drug effects
  • Pituitary Gland / pathology*
  • Pituitary Gland / surgery
  • Prolactinoma / drug therapy
  • Prolactinoma / surgery*
  • Prolactinoma / therapy*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Dopamine Agonists